NASDAQ: OMCL · Healthcare Information Services
Omnicell (OMCL) fair value: undervalued or overvalued?
As of 27 Sep 2026, Faircurve's model values Omnicell (OMCL) at $37.83 a share. The stock last closed at $33.60, which puts the model's fair value 12.6% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Omnicell, Inc.
Faircurve Insights · 27 Sep 2026
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Faircurve's model found a fair value of $37.83 a share for Omnicell, Inc. on 27 Sep 2026, the midpoint of 2,000 simulations. This fair value moved +2.5% since the previous run on 19 Sep 2026, which gave $36.89. The calibrated range over 63 trading days is $31.74 to $46.13, built from the fair value, and ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium.
The overall quality score against comparable companies is 64 out of 100. The model compares Omnicell, Inc. with Certara, Inc. (CERT), HealthStream, Inc. (HSTM), Waystar Holding Corp. (WAY), Doximity, Inc. (DOCS), and BrightSpring Health Services, Inc. Common Stock (BTSG). The stock's median move around its last 8 earnings reports, ignoring direction, was 14.4%.
Written from the figures on this page for the 27 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give OMCL?
The calibrated range for OMCL over 63 trading days is $31.74 to $46.13. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $31.32 to $44.93. In 70% of the simulations the fair value came out above the price the model ran on.
How does OMCL score on business quality?
Omnicell's overall quality score is 64 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 38 | 3.2%ROIC | -4.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 90 | 3.62xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 52 | 6.5%Revenue growth, trailing | 9.4% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 77 | 4.1%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 91 | -0.87xNet debt / EBITDA | 1.76x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 76 | 1.7 ptsEBITDA margin downside volatility, 5y | 6.4 pts |
How does OMCL compare with similar companies?
The companies in healthcare information services closest to Omnicell in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| CERT Certara, Inc. | $9.36 | $8.92 | -4.7% | Fairly valued |
| HSTM HealthStream, Inc. | $30.82 | $28.05 | -9.0% | Fairly valued |
| WAY Waystar Holding Corp. | $24.81 | $27.53 | +11.0% | Fairly valued |
| DOCS Doximity, Inc. | $27.93 | $25.91 | -7.2% | Fairly valued |
| HQY HealthEquity, Inc. | $90.04 | $90.09 | +0.1% | Low evidence grade |
| BTSG BrightSpring Health Services, Inc. Common Stock | $60.25 | $66.74 | +10.8% | Fairly valued |
All healthcare information services stocks ranked by gap to fair value
When does OMCL report earnings, and how has the stock reacted?
Omnicell's next earnings report is scheduled for 29 Oct 2026. Companies can move their dates.
How OMCL moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 14.4%.
| Report date | Two session move |
|---|---|
| 30 Jul 2026 | -14.6% |
| 28 Apr 2026 | +14.5% |
| 5 Feb 2026 | -20.6% |
| 30 Oct 2025 | +13.5% |
| 31 Jul 2025 | +0.2% |
| 6 May 2025 | -14.3% |
| 6 Feb 2025 | -9.5% |
| 30 Oct 2024 | +21.2% |
Omnicell at a glance
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
- Market value
- $1.5B
- Sector
- Healthcare
- Industry
- Healthcare Information Services
- Revenue expected, next twelve months
- $1.3B
- Consensus revenue growth, next fiscal year
- +4.4%
- Analysts with estimates
- 5
- Beta to the US market
- 0.95
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Omnicell on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for OMCL was $36.89. As of 27 Sep 2026 it is $37.83, a change of +2.5%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Omnicell's valuation
Is Omnicell stock undervalued or overvalued?
On Faircurve's model, OMCL reads as Fairly valued as of 27 Sep 2026. The model's fair value is $37.83 a share against a last close of $33.60, a gap of +12.6%.
What is OMCL's fair value?
$37.83 a share as of 27 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $31.32 to $44.93.
What price range does the model give OMCL?
$31.74 to $46.13 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Omnicell report earnings next?
The next report is scheduled for 29 Oct 2026. Companies can move their dates.
How much has OMCL moved on past earnings reports?
Across its last 8 reports the median two session move was 14.4%, ignoring direction. The largest was +21.2% around the report of 30 Oct 2024.
How confident is the model in this valuation?
The model's evidence grade for OMCL is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.